Acute severe colitis: Infliximab and/or cyclosporine?

Mauro Fabro, Hajnalka Szabo, Giovanni Terrosu, Claudio Avellini, Maria Tabuso, Gionata Fiorino, Dario Sorrentino

Research output: Contribution to journalArticle

Abstract

Acute severe ulcerative colitis is a serious condition that requires early hospitalization, with intensive monitoring and treatment. Despite the recent progress in the medical approach of Inflammatory Bowel Diseases acute severe ulcerative colitis remains a clinical challenge, with a mortality rate of nearly 1%. As of today, I.V. corticosteroids remain the 1st-line therapy for this complication. For non-responders (up to one-third of patients) possible options are surgery - whose timing is a critical point in the overall management of the disease - or rescue therapy with 2nd- line agents such as Cyclosporine and Infliximab. Here we will review the published studies dealing with the use of these medications in acute severe ulcerative colitis.

Original languageEnglish
Pages (from-to)1448-1453
Number of pages6
JournalCurrent Drug Targets
Volume12
Issue number10
DOIs
Publication statusPublished - Sep 2011

Keywords

  • Colectomy
  • Corticosteroids
  • Cyclosporine
  • Infliximab
  • Severe colitis

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Acute severe colitis: Infliximab and/or cyclosporine?'. Together they form a unique fingerprint.

  • Cite this

    Fabro, M., Szabo, H., Terrosu, G., Avellini, C., Tabuso, M., Fiorino, G., & Sorrentino, D. (2011). Acute severe colitis: Infliximab and/or cyclosporine? Current Drug Targets, 12(10), 1448-1453. https://doi.org/10.2174/138945011796818234